Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion
Glucagon levels are increasingly being included as endpoints in clinical study design and more than 400 current diabetes-related clinical trials have glucagon as an outcome measure. The reliability of immune-based technologies used to measure endogenous glucagon concentrations is, therefore, importa...
| Главные авторы: | , , , , , , , |
|---|---|
| Формат: | Статья |
| Язык: | English |
| Опубликовано: |
Hindawi Limited
2016-01-01
|
| Серии: | Journal of Diabetes Research |
| Online-ссылка: | http://dx.doi.org/10.1155/2016/8352957 |